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STIM1STIM1 is a key regulator of store-operated calcium entry (SOCE), and therefore a mediator of Ca2+ entry-
dependent cellular events. Phosphorylation of STIM1 at ERK1/2 target sites has been described as enhancing
STIM1 activation during intracellular Ca2+ emptying triggered by the inhibition of the sarco(endo)plasmic
Ca2+-ATPase with thapsigargin. However, no physiological function is known for this speciﬁc phosphorylation.
The present study examined the role of STIM1 phosphorylation in cell signaling triggered by EGF. Using a
human endometrial adenocarcinoma cell line (Ishikawa cells) EGF or H-Ras(G12V), an active mutant of H-Ras,
was found to trigger STIM1 phosphorylation at residues Ser575, Ser608, and Ser621, and this process was sensi-
tive to PD0325901, an inhibitor of ERK1/2. Both, ERK1/2 activation and STIM1 phosphorylation took place in the
absence of extracellular Ca2+, indicating that both events are upstream steps for Ca2+ entry activation. Also, EGF
triggered the dissociation of STIM1 from EB1 (a regulator of microtubule plus-ends) in a manner similar to that
reported for the activation of STIM1 by thapsigargin. Migration of the Ishikawa cells was impaired when STIM1
phosphorylation was targeted by Ser-to-Ala substitution mutation of ERK1/2 target sites. This effect was also
observed with the Ca2+ channel blocker SKF96365. Phosphomimetic mutation of STIM1 restored the migration
to levels similar to that found for STIM1-wild type. Finally, the increased vimentin expression and relocalization
of E-cadherin triggered by EGF were largely inhibited by targeting STIM1 phosphorylation, while STIM1-S575E/
S608E/S621E normalized the proﬁles of these two EMT markers.
© 2014 Elsevier B.V. All rights reserved.1 . Introduction
Stromal interaction molecule (STIM1) is a single transmembrane
endoplasmic reticulum protein that activates plasma membrane
Ca2+ channels on the occurrence of conditions that trigger Ca2+ de-
pletion in the endoplasmic reticulum [1]. Transient reduction in the
intraluminal Ca2+ levels leads to Ca2+ dissociation from the EF-
hand domain of STIM1, triggering its multimerization. STIM1 clus-
tering precedes its relocalization underneath the plasma membrane
where it activates Ca2+ entry through store-operated Ca2+ channels
[2,3]. Ca2+ channels activated by STIM1 include some members of
the TRPC channel family, and ORAI channels [4,5], including ORAI1
(also called CRACM1), a highly selective Ca2+ channel responsibleasmic reticulum; EMT, epithelial–
ed kinase; SOCE, store-operated
y andMolecular Biology, School
lvas s/n. 06006-Badajoz, Spain.
jmartin@unex.esfor the Ca2+-release-activated Ca2+ current (ICRAC) [6]. STIM1 is there-
fore a key regulator of Ca2+ entry (SOCE), and its role in physiological
and pathological events that are mediated by Ca2+ mobilization is cur-
rently under investigation. In this regard, it is known that STIM1 partic-
ipates in the signaling that regulates cell migration [7], and recent
evidence supports a role for Ca2+ entry in non-tumor cell proliferation
[8–10], as well as in cell adhesion, migration, and proliferation in a
number of tumor cell types [11–14]. Indeed, the increase of the cytosolic
free Ca2+ concentration ([Ca2+]i) activates the Ca2+-regulated prote-
ase calpain and the Ca2+-stimulated protein tyrosine kinase 2 beta
(PTK2B or PYK2) [12], a known regulator of focal adhesion dynamics.
Consequently, the use of Ca2+ channel blockers or the knockdown of
STIM1 or ORAI channels reduces proliferation and promotes cell cycle
arrest in different tumor cell lines [11–17], indicating that SOCE may
be a potential target in cancer therapy. The mechanisms of STIM1 acti-
vation thus need to be addressed in order to deﬁne potential new
cancer treatment strategies.
One of the mechanisms that mediate the activation of STIM1 is the
unfolding of the protein in response to store depletion into an open
conformation that exposes a STIM1–ORAI1 activating region (SOAR)
and allows it to interact with ORAI1 [18,19]. Another mechanism that
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phorylation of the protein. The full set of phosphoresidues has already
been listed [20–22], and we have previously described how STIM1
activity is modulated by ERK1/2-dependent phosphorylation at resi-
dues Ser575, Ser608, and Ser621 [22]. Constitutive dephosphorylation
of these residues impairs SOCE [22], whereas simulation of constitutive
phosphorylation of STIM1 by means of Ser-to-Glu mutation of the
aforementioned residues enhances STIM1 multimerization and SOCE
in response to Ca2+ store depletion [23]. In our previous reports, STIM1
phosphorylationwas observed under treatmentwith thapsigargin, a spe-
ciﬁc sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) inhibitor [24],
that triggered ERK1/2 activation. Conversely, restoration of intraluminal
Ca2+ levels led to STIM1 dephosphorylation [23], suggesting a role for
as yet undescribed phosphatases in the regulation of STIM1 inactivation.
In addition to ORAI1 and other proteins such as TRPC1 and SERCA
(reviewed in [25]), STIM1 directly binds to the microtubule plus-end
tracking protein EB1 (end-binding protein 1) [26], a protein that
regulates microtubule-growing ends [27,28]. Later, we demonstrated
that STIM1 phosphorylation at ERK1/2 sites leads to the dissociation of
STIM1 from EB1 [23], and that this dissociation enables the multi-
merization of STIM1 inmicrotubule-independent and immobile clusters
that activate Ca2+ channels and Ca2+ entry [23]. However, little is
known regarding the phosphorylation of STIM1 upon physiological
stimuli. ERK1/2 becomes activated by the Ras–Raf–MEK–ERK pathway
in response to a number of stimuli, including the activation of the epi-
dermal growth factor (EGF) receptor [29,30]. Thus, the treatment of
cells with EGF provides an opportunity to study the role of STIM1 phos-
phorylation in response to the activation of this speciﬁc signaling path-
way. Furthermore, EGF triggers a chemotactic response in tumor cells
[31], and is involved in the in vitro epithelial–mesenchymal transition
(EMT) in other cell types [32,33].
Because constitutive dephosphorylation of STIM1 at ERK1/2 target
sites impairs SOCE [22], we hypothesized that phosphorylation of
STIM1 could regulate cell migration. To test this hypothesis, we investi-
gated the phosphorylation proﬁle of STIM1 in cells upon stimulation
with EGF. Using Ishikawa cells, which derive from an endometrial
adenocarcinoma [34], in the present report we demonstrate that EGF
triggers a signiﬁcant phosphorylation of STIM1 at residues Ser575,
Ser608, and Ser621. We also show here the critical role of STIM1 phos-
phorylation at ERK1/2 target sites in cell migration. Ser-to-Ala mutation
of target residues or inhibition of STIM1 phosphorylation by ERK1/2was
found to impair both EGF-dependent chemotaxis and the epithelial–
mesenchymal transition (EMT) triggered by EGF. On the contrary, con-
stitutive phosphorylation signiﬁcantly promoted migration and EMT,
indicating that STIM1 phosphorylation could be considered a potential
therapeutic target against tumor progression.
2 . Materials and methods
2.1. Materials
EGFwas purchased fromSigma;DMEM, RPMI 1640, FBS, andNuPAGE
Bis-Tris gels were from Life Technologies; PD0325901 from Axon
Medchem BV (Groningen, The Netherlands); fura-2-acetoxymethyl
ester (fura-2-AM) was from Calbiochem (a Merck brand, Darmstadt,
Germany); thapsigargin (Tg) and SKF96365were from AbCam Biochem-
icals (Cambridge, UK); SuperSignal substrate for chemiluminescencewas
from Thermo Scientiﬁc; GFP-Trap resin was from Chromotek GmbH
(Planegg-Martinsried, Germany); protein G-sepharose was from Santa
Cruz Biotechnology; polyethyleniminewas purchased from Polysciences,
Inc. (Eppelheim, Germany).
2.2. DNA constructs
DNA constructs for transient expression of STIM1, EB1, STIM1-
S575A/S608A/S621A, and STIM1-S575E/S608E/S621E tagged witheither Flag-, GFP-, or mCherry-, have been described elsewhere [23,
35]. DNA constructs were veriﬁed by DNA sequencing using BigDye
Terminator v3.1 cycle sequencing protocol (Life Technologies) at the
DNA Sequencing Unit of STAB, University of Extremadura (Spain). The
construct for the transient expression of active H-Ras (H-RasG12V,
construct DU20700) was from the Division Signal Transduction and
Therapy (DSTT), University of Dundee, UK.
2.3. Antibodies
Phospho-speciﬁc antibodies raised against phospho-Ser575-STIM1,
phospho-Ser608-STIM1, and phospho-Ser621-STIM1 were produced
in collaboration with the Division of Signal Transduction Therapy
(DSTT), University of Dundee, UK. The speciﬁcity of these antibodies
has been reported elsewhere [23,35]. Antibodies against phosphorylat-
ed (phospho-Thr202/Tyr204) and total forms of ERK1/2 (raised in rab-
bit), and the rabbit anti-GFP antibody were from Cell Signaling
Technology (Danvers, MA, USA). The rabbit polyclonal anti-STIM1 anti-
body was from ProSci Inc. (Poway, CA, USA). The rabbit anti-EB1 anti-
body (H-70) was from Santa Cruz Biotechnology. Anti-vimentin
(Clone V9) was from Sigma-Aldrich (St. Louis, MO, USA), and anti-E-
cadherin was from BD Biosciences (San Jose, CA, USA).
2.4. Cell culture
Ishikawa cells were obtained from the European Collection of
Cell Cultures (ECACC). Cells were cultured in Dulbecco's modiﬁed
Eagle's medium (DMEM) with 5% (v/v) fetal bovine serum (FBS),
2 mM L-glutamine, 100 U/ml penicillin, and 0.1 mg/ml streptomy-
cin. Transfection of cells was performed with 1–2 μg plasmid DNA
per 10-cm dish and polyethylenimine in serum-containing medium,
24–36 h prior to the beginning of the experiments. During the last
12 h, cells were cultured in FBS-free, phenol red-free RPMI 1640 me-
dium supplemented with 2 mM L-glutamine, 100 U/ml penicillin,
and 0.1 mg/ml streptomycin.
2.5. Cell migration assays
In vitro wound-healing assays were performed in 35-mm dishes at
80% cell conﬂuence. The cell monolayer was scratched with a pipette
tip (~500 μm width). Cells were photographed under phase contrast
microscopy (time 0) and cultured as described above for the following
24 h. Thereafter, cells were photographed and quantitative image anal-
ysis of the wound healing was performed with ImageJ software.
2.6. Cell lysis and immunoblot
Cells were cultured for 12 h in FBS-free and phenol red-free RPMI
1640 medium before performing the experiments. After every treat-
ment, cells were immediately placed on ice, washed with ice-cold
PBS, and lysed. The lysis buffer was 50 mM Tris–HCl (pH 7.5),
1 mM EGTA, 1 mM EDTA, 1% (w/v) Igepal, 1 mM sodium ortho-
vanadate, 50 mM sodium ﬂuoride, 5 mM sodium pyrophosphate,
0.27 M sucrose, 0.1% (v/v) 2-mercaptoethanol, 1 mM benzamidine,
and 0.1 mM phenylmethanesulfonyl ﬂuoride. Clariﬁcation was per-
formed after lysis with 1 ml of ice-cold lysis buffer per 10 cm-
diameter dish, and centrifugation at 4 °C for 15 min at 20 000 g. Pro-
tein concentration was determined using the Bradford reagent
(Thermo) and measuring the absorbance at 595 nm. Samples were
reduced by the addition of 10 mM DTT followed by heating at 90 °C
for 4 min before subjecting them to electrophoresis on 8–10% poly-
acrylamide Bis-Tris gels. Protein samples were electroblotted onto
nitrocellulose membranes, and assessed with the following antibod-
ies: anti-STIM1 (1 μg/ml), anti-phosphoSer575-STIM1 (1 μg/ml),
anti-phosphoSer608-STIM1 (1 μg/ml), anti-phosphoSer621-STIM1
(1 μg/ml), anti-phospho-ERK1/2 (1 μg/ml), anti-total-ERK1/2 (1 μg/ml),
235V. Casas-Rua et al. / Biochimica et Biophysica Acta 1853 (2015) 233–243anti-GFP (1.23 μg/ml), anti-EB1 (0.2 μg/ml), anti-E-cadherin (50 ng/ml),
and anti-vimentin (1 μg/ml). All incubations were performed overnight
at 4 °C, in blocking buffer, with gentle shaking. Speciﬁc secondary
antibodies labeled with HRP were used at 1:10 000–20 000 dilution, for
1 h at room temperature.
2.7. Pull-down and immunoprecipitation
GFP-tagged STIM1 or EB1 were puriﬁed as indicated elsewhere [22,
23]. Equilibrated GFP-Trap agarose beads (5 μl) were added to clariﬁed
cell lysates (3–6 mg), followed by incubation for 1 h at 4 °C with gentle
shaking. In immunoprecipitation assays the beads were washed twice
with 1 ml lysis buffer containing 0.5 M NaCl and twice with 50 mM
Tris–HCl, 0.1 mM EGTA, pH 7.5. In co-immunoprecipitation assays,
GFP-Trap beads were washed twice with 1 ml lysis buffer containing
0.15MNaCl and twicewith 50mMTris–HCl, 0.1mMEGTA, pH 7.5. Pro-
teins were eluted from the beads by the addition of 7 μl NuPAGE-LDS
sample buffer to the beads. Eluted proteins were reduced by the
addition of 10 mMDTT followed by heating at 90 °C for 4 min. Luminol
substrate was added and membranes were exposed to chemilumines-
cence ﬁlms for 3 min. Developed ﬁlms were scanned, and the signal
was quantiﬁed by volumetric integration using ImageJ software. To im-
munoprecipitate untagged endogenous EB1, 1 mg of clariﬁed Ishikawa
cell lysate was incubated with 5 μg anti-EB1 antibody covalently conju-
gated to 5 μl protein G-sepharose overnight at 4 °C. The immunoprecip-
itates were washed twice with 5 ml lysis buffer containing 0.15 M NaCl
and once with 5 ml buffer A. The beads were resuspended in sample
buffer and subjected to electrophoresis on a 4–12% polyacrylamide
gel, as indicated above.
2.8. Cytosolic free calcium concentration measurement
Cytosolic free calcium concentration ([Ca2+]i) was measured basi-
cally as described elsewhere [22,23,35]. Ishikawa cells growing on
18 mm-round glass coverslips were incubated with 2 μM fura-2-AM
plus 0.025% Pluronic-F127 for 60 min in serum-free medium. The cells
were then washed with Ca2+-containing HBSS, and placed in the
micro-incubation platform DH-40i (Warner Instruments, Hamden, CT,
USA) of a Nikon TE2000 invertedmicroscope. Ratio ﬂuorescence images
were obtained with excitation ﬁlters of 340 and 380 nm, a 510 nm di-
chroic mirror, and a 520 nm emission ﬁlter (Semrock, Rochester, NY).
Digital images were recorded with a Hamamatsu C9100-02 electron
multiplier CCD camera, controlled by the Metaﬂuor software. All mea-
surements were made at 35 °C. Depletion of Ca2+ stores was triggered
by incubating cells with 1 μM thapsigargin in Ca2+-free HBSS with the
following composition: 138 mM NaCl; 5.3 mM KCl; 0.34 mM
Na2HPO4; 0.44 mM KH2PO4; 4.17 mM NaHCO3; 4 mM MgCl2; 0.1 mM
EGTA (pH = 7.4). SOCE was measured by monitoring the increase of
the [Ca2+]i after the addition of 2 mM CaCl2 to the Tg-containing
medium [22,23,35].
2.9. Immunolocalization
Ishikawa cells were ﬁxed in 4% paraformaldehyde for 10 min at
room temperature. Then they were permeabilized with 0.2% Triton
X-100 for 10 min and incubated in blocking solution (3% coldwater
ﬁsh skin gelatin diluted in PBS-Tween 0.2%, pH 7.4) for 30 min at
room temperature. Cells were incubated at room temperature for
1 h with the speciﬁc antibody, either anti-vimentin (1:50) or anti-
E-cadherin (1:100) diluted in blocking solution, and then incubated
at room temperature for 20 min with an anti-mouse IgG antibody
labeled with Alexa Fluor-488 diluted 1:500 in blocking solution.
Samples were counterstained with Hoechst 33342 (0.2 μg/ml) for
5 min, and were visualized by epiﬂuorescence microscopy with a
Superﬂuor 100× (NA 1.3) oil immersion objective in an inverted
TE2000-U Nikon microscope.2.10. Statistical analysis
Statistical analyses were done by the one-way analysis of variance
(ANOVA). Differences between groups of data were considered statisti-
cally signiﬁcant for p b 0.05. Values are represented as follows:
*p b 0.05, **p b 0.01 and ***p b 0.001.
3 . Results
3.1. EGF activates Ca2+ inﬂux in Ishikawa cells
In order to establish a protocol for studying STIM1 phosphorylation,
and given that culturing cells in the presence of FBS stimulates diverse
signaling pathways, we compared ERK1/2 activation in Ishikawa cells
in two different culture media, DMEM and RPMI 1640, in the absence
of FBS for 12 h (Fig. 1A). FBS deprivation is a common protocol with
which to maintain low stimulation of cells in culture. We observed
that FBS-free, phenol red-free RPMI 1640 avoided undesired activation
of ERK1/2 activation during this timeof incubation. For the following ex-
periments, therefore, we cultured Ishikawa cells in FBS-supplemented
DMEM until they reached the desired conﬂuence, and then cells were
incubated in FBS-free, phenol red-free RPMI 1640 for 12 h. Following
this protocol we studied the activation of store-operated Ca2+ entry
(SOCE) by Ca2+ store depletion triggered with thapsigargin (Tg)
(Fig. 1B). Fura-2-loaded cells were treated with Tg, an inhibitor of
the SERCA, in Ca2+-free medium, and we observed the consequent
release of Ca2+ from the endoplasmic reticulum, the Tg-sensitive in-
tracellular Ca2+ store. The subsequent addition of Ca2+ to the assay
medium revealed the increase of Ca2+ entry (SOCE) that was signif-
icantly inhibited by 10 μM SKF96365, a blocker of Ca2+ channels
(Fig. 1B). At lower concentrations of SKF96365 (1 μM and 5 μM),
the inhibition was partial.
As mentioned above, we had recently demonstrated that the phos-
phorylation of STIM1 by ERK1/2 regulates the activation of Ca2+ entry
in HEK293 cells [22,23]. Because the ERK pathway is activated by EGF,
we hypothesized that the EGF signaling pathway could be mediated
by the phosphorylation of STIM1 under EGF-dependent ERK1/2 activa-
tion, and possibly by the activation of STIM1-dependent Ca2+ entry
pathways. To test this hypothesis we measured the cytosolic free Ca2+
concentration ([Ca2+]i) in fura-2-loaded Ishikawa cells stimulated
with EGF (10 ng/ml) (Fig. 1C–D) and we found that EGF elicited cyto-
solic Ca2+ spikes in Ca2+-free medium, i.e. transient spikes of Ca2+ re-
leased from the intracellular stores. After 10 min of stimulation we
added Ca2+ back to the assay medium, and observed a patent Ca2+
entry that was inhibited by 10 μM SKF96365, conﬁrming the activation
of Ca2+ entry by EGF in Ishikawa cells.
3.2. EGF triggers STIM1 phosphorylation and STIM1–EB1 dissociation
Following a similar experimental procedure, we monitored the acti-
vation of ERK1/2 by MEK1/2-dependent phosphorylation in Ishikawa
cells stimulated with EGF. Using phospho-speciﬁc antibodies to detect
pThr202/pTyr204-ERK1/2, we observed a signiﬁcant activation of
ERK1/2 after 10min of stimulation with 10 ng/ml EGF in Ca2+-free me-
dium. This activation of ERK1/2 was fully prevented by PD0325901
(Fig. 2A), a recognized inhibitor of MEK1/2 [36]. Our results thus
demonstrated that extracellular Ca2+ was not required to activate the
MEK–ERK pathway in response to EGF stimulation. In parallel, we stud-
ied the phosphorylation proﬁle of STIM1 at ERK1/2 target sites using
phospho-speciﬁc antibodies against STIM1 residues Ser575, Ser608,
and Ser621. We have recently reported the speciﬁcity of these antibod-
ies, the absence of cross-reactivity, and the lack of sensitivity for the
non-phosphorylated STIM1 [23,35]. Ishikawa cells were transfected
for the transient expression of STIM1-GFP (wild type), and after 24 h
of culture the cells were treated with 10 ng/ml EGF in Ca2+-free medi-
um for 10 min. Total lysates from these cells were used to pull-down
Fig. 1. EGF-triggered Ca2+mobilization in Ishikawa cells. (A) Ishikawa cells were cultured in DMEM containing 5% FBS (ﬁrst set of lanes), and then transferred to FBS-free, phenol red-free
RPMI 1640 medium for 12 h (second set of lanes), or transferred to FBS-free DMEM (last set of lanes). Lysates from cells (20 μg) were subjected to electrophoresis and subsequent im-
munoblot using anti-phospho-Thr202/Tyr204-ERK1/2 (labeled as pERK1/2, upper panel) and anti-total-ERK1/2 antibodies to evaluate activation of ERK1/2. (B) SOCE was evaluated in
fura-2-loaded Ishikawa cells after the addition of 1 μM thapsigargin (Tg) in Ca2+-free HBSS followed by the addition of 2 mM CaCl2 to the assay medium. The ratio F340/F380 was mon-
itored by epiﬂuorescence as indicated in Materials andMethods. SKF96365, at the indicated concentrations, was added together with Tg. Traces are mean ± s.d. of 4 independent exper-
iments (N60 cells per experimental condition). Fura-2-loaded Ishikawa cellswere treatedwith 10 ng/ml EGF inCa2+-freeHBSS. After 6min, 2mMCaCl2was added to the assaymedium, in
the absence (C) or presence (D) of 10 μMSKF96365. Data are representative traces of 4 independent experiments (N30 cells per experimental condition). (E) The increase in the F340/F380
ratio after Ca2+ addition was evaluated from the experiment shown in panels C–D.
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Ser608 and phospho-Ser621 by immunoblot (Fig. 2B). The quantiﬁca-
tion of these immunoblots showed that EGF signiﬁcantly stimulated
the phosphorylation of STIM1 at Ser575, Ser608, and Ser621 after
10 min (Fig. 2C), demonstrating that STIM1 phosphorylation at ERK1/2
target sites was concomitant with the activation of the MEK–ERKFig. 2. EGF triggers phosphorylation of STIM1 at ERK1/2 target sites. (A) Ishikawa cells were tre
phospho-ERK1/2 by immunoblot. Loading control was monitored with an anti-total-ERK1/2 an
inhibitor PD0325901 (0.5 μM). Blots are representative of 3 independent experiments with 3 d
STIM1-GFP were treated with 10 ng/ml EGF in Ca2+-free HBSS for 10 min. Total lysates were
STIM1 by immunoblot. Total level of STIM1-GFPwas evaluatedwith an anti-GFP antibody. In pa
as in panel A. Total ERK1/2 levels were also monitored as loading control. Blots are representat
phorylated STIM1 observed in blots from panel B was performed by blot densitometry after sub
calculatedmean± s.d. (D) Ishikawa cells were co-transfected for the transient expression of ST
STIM1, phospho-Ser608-STIM1, and phospho-Ser621-STIM1 by immunoblot. Incubation of ce
of STIM1-GFP were also evaluated with an anti-GFP antibody. The determination of phospho-
independent experiments with 3 different lysates.pathway by EGF, and that this phosphorylation occurred in the absence
of extracellular Ca2+, i.e., Ca2+ entry is not required to trigger either
the activation of ERK1/2 or STIM1 phosphorylation at ERK1/2 target
sites upon EGF stimulation. Moreover, PD0325901 prevented STIM1
phosphorylation, further demonstrating the role of ERK1/2 in STIM1
phosphorylation in Ishikawa cells stimulated with EGF.ated with 10 ng/ml EGF in Ca2+-free HBSS for 10min. Total lysates were used to evaluate
tibody (lower blot). As a control of the experiment, cells were incubated with the ERK1/2
ifferent lysates. (B) As in panel A, Ishikawa cells transfected for the transient expression of
used to evaluate phospho-Ser575-STIM1, phospho-Ser608-STIM1, and phospho-Ser621-
rallel, the determination of the level of ERK1/2 stimulationwas performed by immunoblot,
ive of 4 independent experiments with 4 different lysates. (C) Quantiﬁcation of the phos-
tracting the background for each blot lane, using ImageJ software. Data correspond to the
IM1-GFP and H-Ras(G12V), and after 24 h cell lysates were assessed for phospho-Ser575-
lls with PD0325901 (0.5 μM) was carried out in the 20 min before cell lysis. Total levels
ERK1/2 and total ERK1/2 levels was performed as in panel B. Blots are representative of 3
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sion of the GTPase H-Ras(G12V), a constitutively active mutant of H-Ras,
leads to the increase of STIM1 phosphorylation at ERK1/2 target sites
(Fig. 2D). H-Ras, also known as p21ras, is an upstream activator of the
Raf–MEK–ERK signal transduction pathway, and an essential mediator forEGF-dependent activation of this signaling pathway [37]. In addition, the
phosphorylation of STIM1 triggered by H-Ras(G12V)was largely attenuat-
ed by PD0325901, conﬁrming the role of ERK1/2 in this phosphorylation.
On the other hand, we have recently reported that phosphorylation
of STIM1 at Ser575, Ser608, and Ser621 triggers its dissociation from
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bule plus-ends [27,28]. However, our previous ﬁndings were observed
in cells treated with Tg, a severe but non-physiological stimulus. Here,
we investigated whether EGF triggered STIM1–EB1 dissociation by
transfecting Ishikawa cells with EB1-GFP and Flag-STIM1, and stimu-
lating cells with 10 ng/ml EGF. We then pulled-down EB1-GFP and
studied the level of co-precipitated Flag-STIM1 by immunoblot
(Fig. 3A). The results indicated that EGF stimulated the dissociation
of STIM1 from EB1. This result was also supported by the observed
dissociation between STIM1–EB1 when we immunoprecipitated en-
dogenous EB1 and studied co-immunoprecipitated endogenous STIM1
(Fig. 3B). Therefore our results provide evidence that the MEK–ERK–
STIM1 pathway becomes activated by EGF, and that this activation re-
leases STIM1 from microtubule tips, a key event for the activation of
SOCE [23].
The present result is also novel, in the sense that it constitutes the
ﬁrst reported evidence for the phosphorylation of STIM1 by ERK1/2,
and for STIM1–EB1 dissociation upon physiological stimulation.
3.3. Phosphorylation of STIM1 is required to trigger cell migration
Given the chemotactic activity of EGF on epithelial cells, we investi-
gated the role of Ca2+ entry and STIM1 phosphorylation on the cell mi-
gration of Ishikawa cells in response to stimulation in wound-healingFig. 3. EGF induces dissociation of STIM1 fromEB1. (A) Ishikawa cellswere transfected for transi
treatedwith 10 ng/ml EGF in Ca2+-free HBSS for 10min. GFP-tagged EB1 from these cells was p
using an anti-STIM1 antibody (upper panel), and the level of pulled-down EB1-GFP was evalua
each experimental condition are shown (input). Finally, to test ERK1/2 activation by EGF treatme
was performed by blot densitometry after subtracting the background for each blot lane, using
cultures. (B) Ishikawa cells were treated with 10 ng/ml EGF in Ca2+-free HBSS for 10 min and e
jugated to protein G-sepharose. The level of immunoprecipitated EB1 was evaluated with the
anti-STIM1 antibody. As a negative control, lysates were incubated with protein G-sepharose i
precipitation was performed by blot densitometry, using ImageJ software. Blots are representaassays (Fig. 4). The potentiation of cell migration by EGF was inhibited
by 1 μM SKF96365, a concentration of the inhibitor that partially
blocked Ca2+ entry but did not have any detrimental effect on cell via-
bility. Interestingly, the ERK1/2 inhibitor PD0325901 also signiﬁcantly
blocked EGF-stimulated cell migration (Fig. 4A). These two results,
together with the fact that EGF triggers the phosphorylation of STIM1,
suggested a role for STIM1 phosphorylation in the control of cell migra-
tion. To study this hypothesis further, we transiently transfected
Ishikawa cells for the expression of: (i) Flag-STIM1 (wild type);
(ii) Flag-STIM1-S575A/S608A/S621A, i.e., with Ser-to-Ala substitution
mutations at ERK1/2 target sites, in order tomimic constitutive dephos-
phorylation at those sites; and (iii) Flag-STIM1-S575E/S608E/S621E, to
mimic constitutive phosphorylation of STIM1. After 24 h, cells were
assessed for cell migration in wound-healing assays, and we found
that the overexpression of STIM1-S575A/S608A/S621A signiﬁcantly
inhibited cell migration stimulated by EGF (Fig. 4A). On the contrary
STIM1-S575E/S608E/S621E normalized cell migration in wound-
healing assays, conﬁrming that the phosphorylation of STIM1 at ERK1/
2 target sites regulates cell migration. In parallel, we analyzed the
overexpressed STIM1 protein levels in this assay to ensure that this
effect was not dependent on a level of protein expression that varied
between different constructs. After monitoring the wound healing by
phase contrast microscopy, cells were lysed, and total lysates were
assessed for the evaluation of overexpressed Flag-STIM1 by immunoblotent expression of Flag-STIM1 and EB1-GFP. Twenty-four hours after transfection, cellswere
ulled-downwith GFP-Trap. The level of STIM1 bound to EB1was evaluated by immunoblot
ted with an anti-GFP antibody. Total amounts of EB1-GFP and Flag-STIM1 from lysates in
nt, wemonitored phospho-ERK1/2 and total ERK1/2. Quantiﬁcation of STIM1–EB1 binding
ImageJ software. Blots are representative of 3 independent experiments with 3 different
ndogenous EB1 from these cells was immunoprecipitated with an anti-EB1 antibody con-
anti-EB1 antibody, and the level of co-immunoprecipitated STIM1 was evaluated with an
n the absence of anti-EB1 antibody (ﬁrst lane). Quantiﬁcation of STIM1–EB1 co-immuno-
tive of 2 independent experiments with 2 different cultures.
Fig. 4. Targeting STIM1 phosphorylation inhibits EGF-induced cell migration. (A) Ishikawa cells were transfected for the expression of Flag-STIM1, Flag-STIM1-S575A/S608A/S621A, or
Flag-STIM1-S575E/S608E/S621E. Transfection with an empty vector was used as negative control. When cells reached 70% conﬂuence, the cell monolayer was scratched and incubated
with 10 ng/ml EGF for the following 24 h.When SKF96365 (1 μM) or PD0325901 (0.5 μM)was used, they were added to the culturemedium together with EGF. Cells were photographed
and quantitative image analysis was performedwith ImageJ software. Data are presented as themean± s.d. of 4 independent experiments in triplicate. (B) After saving images from the
experiment shown in panel A, total lysates of those cells were assessed for the expression of total STIM1 by immunoblot using an anti-STIM1 antibody in order to discard differences in
STIM1 expression. Bar scale = 200 μm (shown for empty vector and time = 0).
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used in this experiment under every experimental condition, conﬁrming
that dephosphorylation of STIM1 at ERK1/2 largely impairs cell
migration.
3.4. STIM1 mediates the epithelial–mesenchymal transition triggered
by EGF
It is known that EGF triggers an epithelial–mesenchymal transition
(EMT) in Ishikawa cells [38], stimulating the decrease of epithelial
markers and the concomitant increase of mesenchymal markers. Con-
sequently, we hypothesized that the observed impaired migration ofcells expressing Flag-STIM1-S575A/S608A/S621Amight be due to a de-
creased EMT. To this end, we studied the proﬁle of expression and
localization of both E-cadherin and vimentin (two well recognized epi-
thelial and mesenchymal markers) in Ishikawa cells treated with EGF.
Fig. 5A shows that EGF triggers a signiﬁcant switch in E-cadherin local-
ization from subplasma membrane region to a more diffusely localiza-
tion throughout the cytosol, as described for other epithelial cells
which show that E-cadherin is sequestered into perinuclear vesicles
during EMT [40]. Also, EGF triggered an increase of vimentin expression
(see immunoblot in Fig. 5A) in well-deﬁned cytoskeletal localization, in
agreement with the behavior described for other epithelial cells upon
EGF stimulation [39,40]. To evaluate the role of STIM1 phosphorylation
Fig. 5. Phosphorylationof STIM1mediates EMT in Ishikawa cells. (A) The immunoblot and immunolocalizationof vimentin or E-cadherinwereperformed to evaluate the level of expression and
localization of these EMTmarkers in untreated cells vs EGF-treated cells (10 ng/ml for 24 h). Cells were counterstained with Hoechst 33342 for nuclei staining. Note that vimentin shows the
typical intermediateﬁlament proﬁle, whereas E-cadherin shows a peripheral localization restricted to cell–cell junctions in unstimulated cells, and relocalized to the cytosol in EGF-treated cells.
Bar scale = 20 μm. (B) The immunolocalization of vimentin was performed on Ishikawa cells transfected for the expression of STIM1-(wild type)-mCherry (black bar), STIM1-S575A/S608A/
S621A-mCherry (gray bar), STIM1-S575E/S608E/S621E-mCherry (striped bar), and untransfected cells (white bar). Then, cells were stimulated with EGF as indicated in panel A. Within the
STIM1-mCherry positive cells, we calculated vimentin-positive cells by counting randomly chosen ﬁelds (a minimum of 50 STIM1-mCherry-expressing cells per experiment), shown in bars.
Representative images are shown of EGF-treated cells from this experiment. (C) Similarly, the immunolocalization of E-cadherinwas performed on Ishikawa cells transfected for the expression
of STIM1-(wt)-mCherry (black bar), STIM1-S575A/S608A/S621A-mCherry (gray bar), STIM1-S575E/S608E/S621E-mCherry (striped bar), and untransfected cells (white bar). Within the
STIM1-mCherry positive cells, we evaluated the number of cells with peripheral localization of E-cadherin by counting randomly chosen ﬁelds (a minimum of 50 STIM1-mCherry-expressing
cells per experiment), and representative images are shownof EGF-treated cells. Data are presented as themean±s.d. of 3 independent experiments performed in duplicate. Bar scale=20 μm.
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sient expression of STIM1 (wild type)-mCherry, STIM1-S575A/S608A/
S621A-mCherry, or STIM1-S575E/S608E/S621E-mCherry. After 24 h of
stimulation with EGF, cells that expressed STIM1 (wild type)-mCherry
showed a signiﬁcant increase of vimentin expression and relocalized
E-cadherin to the cytosol (Fig. 5B–C). However, cells overexpressing
STIM1-S575A/S608A/S621A-mCherry did not show any signiﬁcant in-
crease in the expression of vimentin, whereas E-cadherin localization
remained as in untreated cells. On the contrary, the overexpression of
the phosphomimeticmutant STIM1-S575E/S608E/S621E-mCherry sup-
ported EMTequally aswell as in cells transfectedwith STIM1-wild type-
mCherry, i.e., loss of ﬁlamentous E-cadherin and higher expression of
vimentin in cells responding to treatment with EGF, conﬁrming that
phosphorylation of STIM1 at ERK1/2 sites mediates EMT in Ishikawa
cells. The involvement in cell migration and EMT indicates that phos-
phorylation of STIM1 could merit consideration as a new pharmacolog-
ical target for the treatment of cancer, a possibility thatwill need further
experimental conﬁrmation in animal models.
4 . Discussion
The Ras–Raf–MEK–ERK pathway is a downstream effector of tyro-
sine kinase receptors, including the epidermal growth factor receptor
(EGFR), one of themost frequently mutated or overexpressed receptors
in human cancers. Consequently, therapies that are based on targeting
this signaling pathway have attracted the attention of current pharma-
cological investigation [29]. In this regard, activating mutations in the
B-Raf isoform of the Raf kinase, or K-Ras isoform of the Ras protein
are found in approximately 30% of all human cancers, with B-Raf(V600E)
being the commonest B-Raf mutation in human carcinogenesis [41].
Therefore, many pre-clinical studies have focused on the use of speciﬁc
inhibitors of the Raf–MEK–ERK pathway in order to evaluate their po-
tential for the treatment of cancer. We have recently shown that
STIM1 is a downstream target of ERK1/2 in vitro and in vivo [22,23],
and that phosphorylation of STIM1 by ERK1/2 modulates Ca2+ entry
by stimulating the dissociation of STIM1 from the microtubule plus-
end-binding protein EB1 [23]. However, our previous ﬁndings were
based on the inhibition of Ca2+ pumping into the ER, without the
activation of any physiological pathway.
Ishikawa cells, derived from an endometrial adenocarcinoma, were
used to show here for the ﬁrst time that the activation of signaling
pathways triggered by EGF leads to STIM1 phosphorylation at ERK1/2
target sites. In this regard, the present results prove that phosphoryla-
tion of STIM1 by ERK1/2 constitutes a way to activate STIM1 under
physiological conditions (i.e., EGF treatment), or upon oncogenic muta-
tion of H-Ras, and not only bydepleting Ca2+ storeswith a SERCA inhib-
itor (thapsigargin). Also, our data show that STIM1–EB1 dissociation
also occurs upon EGF stimulation, not only in response to the severe
and non-physiological intraluminal Ca2+ depletion triggered by
thapsigargin. In this regard, it has been shown that tubastatin-A, a
speciﬁc histone deacetylase 6 (HDAC6) inhibitor, inhibits STIM1
relocalization and blocks SOCE activation in cancer cells [42], but did
not affect the interaction between STIM1 and EB1, a result that ﬁts
well with the proposal that EB1-associated STIM1 does not activate
Ca2+-entry. Similarly, resveratrol inhibits the phosphorylation of
STIM1, leading to the inhibition of the dissociation of STIM1 from EB1
and inhibition of SOCE in HEK293 cells [35]. Although we reported
here that EGF triggers the dissociation of STIM1 from EB1, phosphoryla-
tion of STIM1 is reversible, and a Ca2+ entry-dependent STIM1 dephos-
phorylation was previously shown [23]. That means that there is cyclic
phosphorylation/dephosphorylation, leading to a plausible binding
back to EB1 when STIM1 becomes dephosphorylated. To test whether
microtubules-mediated transport was responsible for the polarization
of STIM1, Tsai et al. expressed an YFP-conjugated EB1-binding deﬁcient
mutant STIM1 (i.e., mutated at Ile644/Thr645), and reporting that YFP-
STIM1-Ile644Asn/Pro645Asn increased SOCE to a similar degree aswildtype YFP-STIM1, indicating that themutantmaintained its full ability to
control Ca2+ inﬂux [7], as we reported previously in [23]. However,
YFP-STIM1-Ile644Asn/Pro645Asn failed to polarize in migrating cells,
suggesting the requirement of STIM1 to bind to EB1 at resting state,
but not for the activation of SOCE. Thus, it is possible that STIM1 can
travel bound to EB1 until reaching a restricted region of the cell with
high Ras–Raf–MEK–ERK-activity, becoming phosphorylated, and then
dissociating from EB1 to activate Ca2+ entry.
Another important conclusion that can be drawn from the results is
that the activation of the MEK–ERK axis does not require the upstream
activation of Ca2+ entry. On the contrary, we observed activation of
ERK1/2 and phosphorylation of STIM1 at ERK1/2 target sites in the
absence of extracellular Ca2+. Therefore Ca2+ inﬂux-independent phos-
phorylation of STIM1 triggered by EGF is an upstream event for STIM1-
dependent cellular events, which constitutes strong support for the pro-
posal that STIM1 phosphorylation modulates Ca2+-entry. Indeed,
STIM1 phosphorylation by ERK1/2 represents a positive feedback for
the Raf–MEK–ERK pathway since it is known that the increase in intra-
cellular Ca2+ levels mediates Ca2+/calmodulin-dependent protein
kinase II (CaMKII)-dependent activation of Raf-1 [43]. These data,
together with the fact that Ishikawa cell migration is largely im-
paired by the Ca2+ channel blocker SKF96365 as well as by the
ERK1/2 inhibitor PD0325901, led us to hypothesize that inhibition
of STIM1 phosphorylation is sufﬁcient to prevent cell migration.
This hypothesis had yet to be explored, but was already supported
by recent ﬁndings showing that the activation of receptor tyrosine
kinase leads to local activation of STIM1 in the front of migrating
endothelial cells [7].
As shown above, in this work we have described how targeting
STIM1 phosphorylation constitutes a mechanism that impairs cell
migration and epithelial–mesenchymal transition in vitro, strongly
supporting a role for STIM1 phosphorylation in these cellular events.
By transfecting Ishikawa cells for the expression of mutated STIM1 at
ERK1/2 target sites,we have shown that constitutive dephosphorylation
reduces the EGF-induced migration rate. Because dephosphorylated
STIM1 remains inactive, our results are in agreement with the ﬁnding
that knocking-down STIM1 expression, by using speciﬁc siRNA,
prevents breast cancer cell migration and metastasis [11], and that
Ca2+ inﬂux activated by STIM1 is required for a proper turnover of
focal adhesions [11]. Moreover, our results indicate that this speciﬁc
phosphorylation of STIM1modulates cellmigration and the transforma-
tion to a mesenchymal-like phenotype, which explains the impairment
of cell migration and EMT when STIM1 remains constitutively dephos-
phorylated. Because the knocking-down of STIM1 has been successfully
used to prevent cell migration and metastasis, we consider that the
phosphorylation of STIM1 on its modulatory domain is an alternative,
easily druggable, target. At the cellular level, migration and invasion
are strongly dependent on microtubule dynamics [44], and therefore
microtubule polymerization has been considered a signiﬁcant target in
cancer therapy to reduce or prevent metastasis [45]. Many agents
such as eribulin, ixabepilone, or cabazitaxel, are currently being used
in phase III clinical trials. These agents either stabilize microtubules or
interfere with microtubule polymerization [46–48]. However, the
cytotoxicity of these drugs is signiﬁcant as they block cell cycle at
G2/M transition [47,49] and have a number of clinical side effects
[50]. Thus, the ERK1/2-dependent phosphorylation of the cytosolic
domain of STIM1 constitutes a potential targetable and restricted
molecular motif that might be worthy of consideration in strategies
intended to prevent cell migration and metastasis when designing
new approaches to the treatment of human cancer.
In conclusion, we have here described solid evidence that EGF trig-
gers phosphorylation of STIM1 at Ser575, Ser608, and Ser621, which
are known targets of ERK1/2 activity. Also, STIM1 phosphorylation
upon EGF stimulation triggers the dissociation of STIM1 from EB1, a
key event in the activation of STIM1. Finally, bymeans of blocking phos-
phorylation of STIM1 or by mimicking this phosphorylation, we have
242 V. Casas-Rua et al. / Biochimica et Biophysica Acta 1853 (2015) 233–243shown that phospho-STIM1 mediates EGF-triggered cell migration and
EMT. This is the ﬁrst report showing that STIM1 is a downstream effec-
tor of the Ras–Raf–MEK–ERK pathway and may contribute to the study
of new roles for STIM1.
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